An Innovative New Treatment Gives Hope to Women Who Have Difficulty Getting Pregnant

Food and Healthcare Press Releases Monday July 15, 2013 15:13
Bangkok--15 Jul--Spark Communications

MSD, one of the leading companies in the development of solutions in the IVF (In Vitro Fertilization) sector, has releaseda ground breaking new treatment for IVF patients which will make their lives a lot easier through a new fertility treatment.

This innovative new treatment gives hope to many women experiencing the emotional and physical stress of infertility issues, which is a sustained release follicle stimulating hormone (FSH) - the first of its kind. One significant benefit of using this new fertility treatment is the few number of treatments needed. Currently, women now undergoing IVF have to have a daily subcutaneous injection of FSH but this new solution means that they will only have to get an injection once a week.

This treatment is the first sustained follicle stimulant. Due to its ability to initiate and sustain multiple follicular growth for an entire week, a single subcutaneous injection of the recommended dose may replace the first seven injections of any the conventional daily follicle stimulating hormone (FSH) injections for controlled ovarian stimulation (COS).

Today, up to 15%of couples globally experience fertility problems. In Thailand, fertility rates are in decline from 4.9 children per woman(1975) to 1.6 children per woman(2013), which is considered to be below the generally accepted level of 2.1 children to maintain current population levels. Infertility is a disease that impairs the body's ability to perform the basic function of reproduction. Many causes including problems with the production of sperm or eggs, with the fallopian tubes or the uterus, endometriosis, frequent miscarriage, as well as hormonal and autoimmune disorders in both men and women.

There are some treatments available for infertility, which include surgery, hormone treatments, insemination and IVF. But in the past treatments were time consuming and painful. MSD's new treatment provides an effective, easy, and patient-focused fertility treatment.

Dr. Somjate Manipalviratn, Clinical Director Obstetrician and Gynecologist as well as a leading reproductive endocrinology and infertility specialist, says: "The advent of this new fertility treatment marks a new era of hope for our patients. Infertility is a relatively common problem worldwide and in Thailand, and this new innovative treatment makes it much easier for both patients and doctors. The solutionis a positive step towards reducing the burden of daily injections for women experiencing difficulty conceiving."


Latest Press Release

APEC#s Rare Disease Action Plan Sets Precedent to Integrate Rare Disease Care by 2025

- Asia-Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF) Rare Disease Network comprises Rare Disease International, Queensland University of Technology and Shire (representing as industry co-chair). - Aims to define, diagnose and...

Grunenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grunenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza(R) (8 % capsaicin) for...

Ascensia Diabetes Care Highlights the Support That Families Provide for People With Diabetes To Mark World Diabetes Day 2018

Today, Ascensia Diabetes Care, a global leading diabetes care company, launched their campaign for World Diabetes Day 2018 to celebrate the important role of families for people with diabetes. They are publishing 38 online artworks that tell the stories...

Qatar Foundation Ushers in New Era of Healthcare With Official Inauguration of Sidra Medicine

Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation (QF), today officially inaugurated Sidra Medicine - a brand new, world-leading women's and children's hospital in Qatar. The grand opening reflects the country's broader focus and...

Singapore National Eye Centre, Singapore Eye Research Institute And Johnson Johnson Vision Set Sights On Halting Global Myopia Epidemic

New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and Johnson & Johnson Vision today announced a...

Related Topics